G. Veerman
YOU?
Author Swipe
View article: Sex and Common Germline Variants Affect the Toxicity Profile and Pharmacokinetics of Alectinib: A Nationwide Cohort Study in Patients With ALK-Positive NSCLC
Sex and Common Germline Variants Affect the Toxicity Profile and Pharmacokinetics of Alectinib: A Nationwide Cohort Study in Patients With ALK-Positive NSCLC Open
Female patients encounter more severe toxicity due to higher alectinib exposure, which warrants further exploration. PPAR-α 209G>A significantly increased relevant alectinib-induced toxicity, most likely due to an increase in alectinib exp…
View article: Clinical implications of nintedanib pharmacokinetics in patients with pulmonary fibrosis
Clinical implications of nintedanib pharmacokinetics in patients with pulmonary fibrosis Open
Nintedanib dose was significantly associated with FVC loss. However, no significant relationship between nintedanib exposure and the occurrence of DLTs was found in this real-world population, and no therapeutic window could be established…
View article: Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced EGFR-Mutated NSCLC
Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced EGFR-Mutated NSCLC Open
No relation was found between osimertinib Cmin,SS and BM development or progression in patients with advanced EGFRm+ NSCLC. This suggests that systemic osimertinib exposure is not a surrogate marker for BM development or progression.
View article: Quantitative modeling of tumor dynamics and development of drug resistance in non‐small cell lung cancer patients treated with erlotinib
Quantitative modeling of tumor dynamics and development of drug resistance in non‐small cell lung cancer patients treated with erlotinib Open
Insight into the development of treatment resistance can support the optimization of anticancer treatments. This study aims to characterize the tumor dynamics and development of drug resistance in patients with non‐small cell lung cancer t…
View article: Exploring the impact of patient‐specific clinical features on osimertinib effectiveness in a real‐world cohort of patients with <i>EGFR</i> mutated non‐small cell lung cancer
Exploring the impact of patient‐specific clinical features on osimertinib effectiveness in a real‐world cohort of patients with <i>EGFR</i> mutated non‐small cell lung cancer Open
Osimertinib is prescribed to patients with metastatic non‐small cell lung cancer (NSCLC) and a sensitizing EGFR mutation. Limited data exists on the impact of patient characteristics or osimertinib exposure on effectiveness outcomes. This …
View article: Influence of Food With Different Fat Concentrations on Alectinib Exposure: A Randomized Crossover Pharmacokinetic Trial
Influence of Food With Different Fat Concentrations on Alectinib Exposure: A Randomized Crossover Pharmacokinetic Trial Open
Background: Alectinib is the keystone treatment in advanced anaplastic lymphoma kinase–positive (ALK+) non–small cell lung cancer (NSCLC). An exposure–response threshold of 435 ng/mL has recently been established, albeit 37% of patients do…
View article: Design and statistics of pharmacokinetic drug-drug, herb-drug, and food-drug interaction studies in oncology patients
Design and statistics of pharmacokinetic drug-drug, herb-drug, and food-drug interaction studies in oncology patients Open
Polypharmacy is becoming increasingly prevalent in society. Patients with polypharmacy are at greater risk for drug-drug interactions, which can influence the efficacy of treatment. Especially, in oncology this is a concern since neoplasms…
View article: Incidence of Bone Metastases and Skeletal-Related Events in Patients With EGFR-Mutated NSCLC Treated With Osimertinib
Incidence of Bone Metastases and Skeletal-Related Events in Patients With EGFR-Mutated NSCLC Treated With Osimertinib Open
Bone metastases and SREs are frequent before and during treatment with osimertinib in EGFR+ NSCLC. Because of these findings and the long OS post-bone metastases, we advocate prescription of bone-targeted agents in these patients and recom…
View article: Improving the tolerability of osimertinib by identifying its toxic limit
Improving the tolerability of osimertinib by identifying its toxic limit Open
Background: Osimertinib is the cornerstone in the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer (NSCLC). Nonetheless, ±25% of patients experience severe treatment-related toxicities. Currently, it is impo…
View article: To quantify the small-molecule kinase inhibitors ceritinib, dacomitinib, lorlatinib, and nintedanib in human plasma by liquid chromatography/triple-quadrupole mass spectrometry
To quantify the small-molecule kinase inhibitors ceritinib, dacomitinib, lorlatinib, and nintedanib in human plasma by liquid chromatography/triple-quadrupole mass spectrometry Open
Multiple small-molecule kinase inhibitors with specific molecular targets have recently been developed for the treatment of cancer. This article reports the development and validation of an ultra-performance liquid chromatography/tandem ma…
View article: Plasma Predictive Features in Treating EGFR-Mutated Non-Small Cell Lung Cancer
Plasma Predictive Features in Treating EGFR-Mutated Non-Small Cell Lung Cancer Open
Although epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are the preferred treatment for patients with EGFR-mutated non-small cell lung cancer (NSCLC), not all patients benefit. We therefore explored the impact of…
View article: Comparison of toxicity and effectiveness between fixed-dose and body surface area-based dose capecitabine
Comparison of toxicity and effectiveness between fixed-dose and body surface area-based dose capecitabine Open
Background: Capecitabine is generally dosed based on body surface area (BSA). This dosing strategy has several limitations; however, evidence for alternative strategies is lacking. Therefore, we analyzed the toxicity and effectiveness of f…
View article: Clinically relevant drug interactions with multikinase inhibitors: a review
Clinically relevant drug interactions with multikinase inhibitors: a review Open
Multikinase inhibitors (MKIs), including the tyrosine kinase inhibitors (TKIs), have rapidly become an established factor in daily (hemato)-oncology practice. Although the oral route of administration offers improved flexibility and conven…